Acquisitions, Divestitures and Other Arrangements (Tables)

12 Months Ended

Dec. 31, 2022

EirGen Pharma Limited [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes fair values of assets acquired as of the acquisition date (in thousands):

Construction in process	$	22,736
Buildings		21,550
Furniture and fixtures		1,089
Definite-lived intangible assets		21,794
Other		775
Total consideration	$	67,944

Viela Bio [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the final values assigned to the assets acquired and the liabilities assumed by the Company along with the resulting goodwill before and after the measurement period adjustments (in thousands):

	Before			Adjustments			After
Deferred tax liabilities, net	$	(457,928	)	$	6,589		$	(451,339	)
Accrued expenses and other current liabilities		(73,401	)		(335	)		(73,736	)
Other long-term liabilities		(22,631	)		—			(22,631	)
Accounts payable		(4,768	)		—			(4,768	)
Accrued trade discounts and rebates		(1,492	)		(373	)		(1,865	)
Marketable securities		400			—			400
Property, plant and equipment		1,747			—			1,747
Other long-term assets		3,253			1,613			4,866
Accounts receivable		8,053			(267	)		7,786
Prepaid expenses and other current assets		16,444			152			16,596
Inventories		149,348			2,300			151,648
Cash and cash equivalents		342,347			—			342,347
In-process research and development		910,000			—			910,000
Developed technology		1,460,000			—			1,460,000
(Liabilities assumed) and assets acquired		2,331,372			9,679			2,341,051
Goodwill		662,719			(9,679	)		653,040
Fair value of consideration paid	$	2,994,091		$	—		$	2,994,091

Schedule of Total Consideration for the Acquisitions

The total consideration for the acquisition was approximately $3.0 billion, including cash acquired of $342.3 million, and was composed of the following (in thousands):

Equity value (54,988,820 shares at $53.00 per share)	$	2,914,407
Net settlements on the exercise of stock options		78,554
Consideration for exchange of Viela stock options		1,130
Total consideration	$	2,994,091

Gain (Loss) on Sale of Assets

The following table presents certain pro forma combined results of the Company and Viela for the years ended December 31, 2021 and 2020 as if the acquisition of Viela had occurred on January 1, 2020 (in thousands):

	For the Year Ended December 31,
	2021							2020
	As reported		Pro forma adjustments			Pro forma		As reported		Pro forma adjustments			Pro forma
Net sales	$	3,226,410	$	10,588		$	3,236,998	$	2,200,429	$	11,652		$	2,212,081
Net income		534,491		(30,804	)		503,687		389,796		(291,730	)		98,066